ClinicalTrials.gg
RecruitingNCT07300969Tarian-1Updated Oct 8, 2026

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

A Phase 2 interventional study of DT-101 and DT-101 in Major Depressive Disorder (MDD), sponsored by Draig Therapeutics Ltd. Recruiting at 43 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Draig Therapeutics Ltd · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 8, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 216 open to participants now, 258 under way, 26 of them phase 3. Depressive Disorder, Major · United States.

Planned enrollment
254th of 1,323
300 · median 70
Started
2025
with 68 others
Phase 2
271 of 1,500
45 open now
Primary completion
2027-08
later than 120 of 257 live
Registered
1,439th of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 254th largest by planned enrollment of the 1,323 interventional ones that give a count, is one of 69 that started in 2025, is one of 271 in phase 2, reaches primary completion later than 120 of the 257 other live ones, and was the 1,439th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

216 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

211 more — sign in →

All 216 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. Subjects will attend the clinic every couple of weeks complete general health checks and complete questionnaires.

Read the detailed description

The purpose of this study is to compare DT-101 and placebo in adult participants with MDD. The study will also evaluate how safe and well tolerated the study drug is. The clinical study staff will check participants' suitability to take part in the clinical research study by performing physical and neurological examinations, obtaining blood and urine samples, conducting clinical assessments and reviewing medical and treatment history. These tests and assessments will continue throughout the study with the purpose of checking the participants' ongoing suitability and to collect data to analyze the effect that DT-101 may have on their depression symptoms. Participants will also have blood samples taken to allow analysis of how DT-101 is absorbed and used by the body (PK sampling), some blood samples may be retained in order to perform future research that may be useful when looking at whether genetics affects how a person responds to DT-101 (PGx sampling)

03

Conditions studied

  • Major Depressive Disorder (MDD)

Keywords

  • MDD
  • Depression
  • DT-101
  • randomized
  • placebo controlled
  • major depressive disorder
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant is able to read, understand and communicate in the local language used at the study site, and is willing to provide written
  • Male or female (assigned at birth, inclusive of all gender identities) participant must be 18 to 75 years of age, inclusive at the time of signing the informed consent.
  • Has recurrent depression (defined as at least one prior episode excluding the current one), as diagnosed by DSM 5-TR (, 2022).

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding or plans to become pregnant during the study.
  • Unstable medical condition or unstable chronic disease.
  • Significant neurological abnormality.
  • History of moderate or severe alcohol or drug use disorder as per in the 6 months prior to Screening.
  • History of seizure.
  • In the investigator's opinion, the participant is not capable of adhering to the protocol requirements.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    DT-101 A

    Drug: DT-101

  • Experimental
    DT-101 B

    Drug: DT-101

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugDT-101

    DT-101 A

  • DrugDT-101

    DT-101 B

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change from baseline in total Montgomery Åsberg depression rating scale (MADRS) score, at Day 42

    Time frame: from enrollment to day 42

Secondary outcomes

  1. Change from baseline in Clinician Global Impression of severity (CGI-S), at Day 42

    Time frame: From enrollment until day 42

07

Study locations

40 of 43 sites recruiting
  • Draig Clinical Site
    Bentonville, Arkansas 72712, United States
    Recruiting
  • Draig Clinical Site
    Little Rock, Arkansas 72211, United States
    Recruiting
  • Draig Clinical Site
    Oceanside, California 92056, United States
    Recruiting
  • Draig Clinical Site
    San Diego, California 92103, United States
    Recruiting
  • Draig Clinical Site
    Torrance, California 90502, United States
    Recruiting
  • Draig Clinical Site
    Miami, Florida 33166, United States
    Recruiting
  • Draig Clinical Site
    New Port Richey, Florida 34652, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Draig Clinical Site
    Orlando, Florida 32803, United States
    Recruiting
  • Draig Clinical Site
    Atlanta, Georgia 30331, United States
    Recruiting
  • Draig Clinical Site
    Decatur, Georgia 30030, United States
    Recruiting
  • Draig Clinical Site
    Gaithersburg, Maryland 20877, United States
    Recruiting
  • Draig Clinical Site
    Watertown, Massachusetts 02472, United States
    Recruiting
  • Draig Clinical Site
    Flowood, Mississippi 39232, United States
    Recruiting
  • Draig Clinical Site
    Las Vegas, Nevada 89102, United States
    Recruiting
  • Draig Clinical Site
    Marlton, New Jersey 08009, United States
    Recruiting
  • Draig Clinical Site
    New York, New York 10312, United States
    Recruiting
  • Draig Clinical Site
    Media, Pennsylvania 19372, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Draig Clinical Site
    Austin, Texas 78737, United States
    Recruiting
  • Draig Clinical Site
    Austin, Texas 78754, United States
    Recruiting
  • Draig Clinical Site
    DeSoto, Texas 75115, United States
    Recruiting
  • Draig Clinical Site
    Richardson, Texas 75243, United States
    Recruiting
  • Draig Clinical Site
    Wichita Falls, Texas 76309, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Draig Clinical Site
    Bellevue, Washington 98004, United States
    Recruiting
  • Draig Clinical Site
    Kazanlak, 6100, Bulgaria
    Recruiting
  • Draig Clinical Site
    Plovdiv, 4000, Bulgaria
    Recruiting
  • Draig Clinical Site
    Sofia, 1113, Bulgaria
    Recruiting
  • Draig Clinical Site
    Sofia, 1202, Bulgaria
    Recruiting
  • Draig Clinical Site
    Sofia, 1510, Bulgaria
    Recruiting
  • Draig Clinical Site
    Sofia, 1606, Bulgaria
    Recruiting
  • Draig Clinical Site
    Vratsa, 3000, Bulgaria
    Recruiting
  • Draig Clinical Site
    Ostrava, 70868, Czechia
    Recruiting
  • Draig Clinical Site
    Prague, 10000, Czechia
    Recruiting
  • Draig Clinical Site
    Říčany, 25101, Czechia
    Recruiting
  • Draig Clinical Site
    Gdansk, 80-952, Poland
    Recruiting
  • Draig Clinical Site
    Katowice, 40-156, Poland
    Recruiting
  • Draig Clinical Site
    Poznan, 60-835, Poland
    Recruiting
  • Draig Clinical Site
    Chester, CH2 1HX, United Kingdom
    Recruiting
  • Draig Clinical Site
    Eastbourne, BN23 5UZ, United Kingdom
    Recruiting
  • Draig Clinical Site
    Glasgow, PA1 1JS, United Kingdom
    Recruiting
  • Draig Clinical Site
    London, EC2Y 8EA, United Kingdom
    Recruiting
  • Draig Clinical Site
    London, SE5 8AF, United Kingdom
    Recruiting
  • Draig Clinical Site
    Nottingham, NG7 2TU, United Kingdom
    Recruiting
  • Draig Clinical Site
    Oxford, OX3 7JX, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Aug 2027, 20 months after the start.

Of 99 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's planned 20 months is above that.

Counting every sponsor, half of 198 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2025
First posted
Dec 24, 2025
StartActual
Dec 16, 2025
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites changed recruiting status (3 now terminated)
Show 3 sites
  • Draig Clinical Site · New Port Richey, United StatesRecruiting→Terminated
  • Draig Clinical Site · Media, United StatesRecruiting→Terminated
  • Draig Clinical Site · Wichita Falls, United StatesRecruiting→Terminated
Oct 8, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Draig Clinical Site · New Port Richey, United StatesContact removed i•••@draigtherapeutics.com · •••8450
  • Draig Clinical Site · Media, United StatesContact removed i•••@draigtherapeutics.com · •••8450
  • Draig Clinical Site · Wichita Falls, United StatesContact removed i•••@draigtherapeutics.com · •••8450
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    3 sites changed recruiting status (3 now terminated)
    Show 3 sites
    • Draig Clinical Site · New Port Richey, United StatesRecruiting→Terminated
    • Draig Clinical Site · Media, United StatesRecruiting→Terminated
    • Draig Clinical Site · Wichita Falls, United StatesRecruiting→Terminated
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Draig Clinical Site · New Port Richey, United StatesContact removed i•••@draigtherapeutics.com · •••8450
    • Draig Clinical Site · Media, United StatesContact removed i•••@draigtherapeutics.com · •••8450
    • Draig Clinical Site · Wichita Falls, United StatesContact removed i•••@draigtherapeutics.com · •••8450

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07300969
Lead sponsor
Draig Therapeutics Ltd
Responsible party
Sponsor
First posted
Dec 24, 2025
Start date
Dec 16, 2025
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Oct 8, 2026

Study contacts

Chief Medical Officer
Contact
info@draigtherapeutics.com
+44(0)2920028450

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion